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1. Introduction
  Bacille Calmette-Guérin (BCG) vaccination is administered 
in infancy in China with the aim to protect against 
mycobacterial infections such as tuberculosis (TB) and 
leprosy[1]. Failure of BCG vaccination and little effect 
on preventing TB are contributed to the influence of 
environmental mycobacteria, differences between BCG 
strains, inefficient immune response after BCG stimulation, 
genetic factors and malnutrition of populations[2,3].
  Micronutrient deficiencies like vitamin A (VA) and 
vitamin D (VD) are more common in TB patients[4,5]. In 
recent years, there has been renewed interest in the 
biological effects of VA and VD on TB due to the growing 
evidence of the immunomodulatory properties of VA and 
Objective: To investigate whether there is an association between diameter of bacille Calmette-
Guérin (BCG) scars and effect of purified protein derivative (PPD) reaction and to determine 
whether vitamin A (VA) combined vitamin D (VD) supplementation influences the immune 
response to BCG revaccinated in Chinese infants. Methods: A cross-section and 3-month 
community-randomised trial was conducted. A total of 5 629 infants at 3, 6 and 12 months of 
age in Junan County of China were examined for BCG scar formation. Then, 597 revaccinated 
infants were randomly assigned to supplementation (n=307) and control (n=290) groups. The 
supplementation group were daily assigned to 1 500 IU VA and 500 IU VD for 3 months. Then all 
infants were subjected to skin test with PPD. Results: The diameter of BCG scars was positively 
correlated with diameter of skin indurations of PPD (r=0.17, P<0.05) in the 5 629 infants. The rate 
of positive response to PPD was higher in the supplementation group than in the control group 
(96.1% versus 89.7%, P<0.05, prevalence ratio 1.07, 95% CI 1.02-1.12). The prevalence ratio of PPD 
response for the supplementation group compared with that for the control group was 1.07 (95% 
CI 1.01-1.13) for the males and 1.08 (95% CI 1.00-1.17) for the females. For the supplementation 
group, the males got larger tuberculin induration than the females [(0.73±0.21) cm versus (0.67±0.20) cm,
P<0.05) after intervention. Conclusions: The diameter of BCG scars was effectively correlated 
with PPD response, which indicates BCG scar formation may be an useful tool to evaluate the 
effect of tuberculosis prevention.VA combined VD supplementation may play an immuno-
regulatory role in BCG revaccination. This may contribute to the prevention of childhood 
tuberculosis.
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VD. VA supplementation has been shown to modulate T 
helper 2 lymphocyte responses in childhood[6]. The active 
VD metabolite, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], 
has been shown to be an important regulator of innate 
and adaptive immune function and modulates the host 
response to Mycobacterium tuberculosis infection. Toll like 
receptor mediated activation of macrophages up-regulates 
expression of the VD receptor, leading to the induction of 
the antimicrobial peptide cathelicidin and growth restriction 
of Mycobacterium tuberculosis[7]. 
  The correlation to vaccine efficacy may be affected by 
sex. For instance, boys develop scars and purified protein 
derivative (PPD) responses more frequently than girls[8], 
but there is no evidence boys are better protected against 
TB after BCG vaccination. Some previous studies have 
suggested sex-differential effect of VA and on response to 
vaccines, when the analyses were conducted separately for 
each sex[9-12]. 
  As the induced immunity is mainly cellular, the immune 
response to BCG vaccination is difficult to be quantified. 
Instead, scar development and response to an immunogenic 
component of BCG, PPD of Mycobacterium tuberculosis, are 
used to measure vaccine response in epidemiologic studies. 
Both scar development and PPD response were reported 
correlated positively with a history of BCG vaccination in 
Asia population[13].
  We aimed to investigate whether there is an association 
between diameter of BCG scars and effect of PPD reaction 
and to examine whether VA combined VD can influence the 
immune response to BCG revaccination evaluated as scar 
formation and response to PPD in vivo in infants. 
2. Material and methods
  
2.1. Subject selection
  Ethical permission for all aspects of this research was 
obtained from the Ethic Review Committees of Center for 
Disease Control of Junan County, and studies were conducted 
according to the principles outlined in the Declaration of 
Helsinki. Parents of study subjects were informed, and each 
final participant submitted informed consent before the 
trials. Healthy infants, who did not respond to PPD test at 
3, 6, 12 months of ages respectively, were enrolled in the 
intervention study. Exclusion criteria included severe or 
chronic illness, moderate to severe injury, surgery during the 
previous month, chronic renal failure, liver disease, heart 
failure, irritability of BCG, and history of other preventive 
inoculation less than 2 weeks.
2.2. Enrollment
  Follow the policy of government, all infants in Junan 
County, Shandong Province were vaccinated intradermally 
in the upper left deltoid region with 0.1 mL BCG vaccine 
(contains 5 tuberculin units ) at birth. A total of 5 629 infants 
at 3, 6 and 12 months of age in 20 towns of Junan County 
from 2011 to 2012 were enrolled in our study.
2.3. Anthropometrics
  Measurements were made by trained assistants when the 
infants were taken to local centers for disease control. The 
length of the infants was measured supinely using a wooden 
measuring board. The weight of the undressed infant was 
measured by weighing machine. The head circumference 
was measured by using a tape rule. 
2.4. Scar formation and in vivo PPD response
  Local assistants documented health status, health care 
contacts, household characteristics and vaccination status 
and also measured the size of the BCG scar. The BCG scars 
of all infants were measured. Subsequently, 0.1 mL PPD was 
injected intradermally on the ventral side of the left forearm. 
Three days later, the infant was taken to the center again, 
and the induration was measured by trained assistants. The 
infants with a PPD response (曒0.5 cm) were categorized as 
“PPD-responders”. Diameter of skin indurations of PPD 曒
1.5 cm accompanied with blister or necrosis was judged as 
a strong response, and X-ray and sputum examination were 
used to determine whether the infants had been infected by 
Mycobacterium tuberculosis.
2.5. Intervention assay
  A community-randomised trial was performed. Of the 5 629 
infants, 608 infants did not respond to PPD test (<0.5 cm) and 
needed to be revaccinated. Because of the difficulty to find 
a legal drug manufactory to make placebo in rural area of 
China, the double-blind trials were not used. Randomization 
was applied to the entire 20 towns of Junan County (using 
a random number generator). The infants in 10 towns were 
divided into supplementation group, while those in other 10 
towns into control group. One infant had moved to another 
place and parents of 10 infants refused to participate into 
intervention. Finally, 307 infants were enrolled in the 
supplementation group and 290 in the control group. All 
subjects were given BCG revaccination. The subjects in the 
supplementation group received VA (1 500 IU) combined VD 
(500 IU) drops (Qingdao Double Whale Pharmaceutical), 1 
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capsule/d for 3 months. The drops were distributed by staffs 
from local centers for disease control. The infants were taken 
to give PPD re-test after 3 months. 
2.6. Statistical analysis
  All the statistical analysis was performed using SPSS, 
version 11.5. Data were tested for normal distribution 
using the Kolmogorov-Smirnov test. Length, weight, head 
circumference and other summarized data are expressed 
as mean ± standard deviation (SD). Diameter of tuberculin 
induration of different age groups was analyzed by one-way 
ANOVA. Size of scar and PPD was analyzed using Student’s t 
tests between and within the intervention groups. Prevalence 
of PPD response between the intervention groups was used 
Chi-square test. Estimates were reported as prevalence ratio 
with 95% confidence intervals (CI) after intervention for the 
supplementation group compared with the control group. 
Correlations between BCG scar formation and tuberculin 
induration were estimated using Pearson’s correlation 
coefficient. Differences and associations were considered 
significant at P<0.05.
3. Results
3.1. Effect of age on scar formation and PPD response
  Details of scar formation and tuberculin testing at each age 
group are shown in Table 1. Real scar formation (>0.2 cm) 
were developed in 5 119 (90.9%) of the vaccinated infants, a 
tiny scar (曑0.2 cm) in 400 (7.1%), and no scar in 110 (2.0%). 
About 89.2% (5 021/5 629) infants responded to PPD (曒0.5 
cm). Totally, 4 994 (88.7%) subjects gave a positive tuberculin 
reaction, 27 (0.5%) gave a strong positive induration, and 
608 (10.8%) gave a PPD-negative response. X-ray and 
sputum examination revealed no evidence of active TB in 65 
infants with a tuberculin induration greater than 1.5 cm or 
displaying blister or necrosis. 
  The median scar size was larger in the males than in the 
females [(0.40±0.15) cm versus (0.38±0.13) cm, P<0.05] in the 
6 months group. The rate of response to PPD was higher in 
the males than in the females in the 3 months group (92.0% 
versus 88.7%, P<0.05) but was higher in females than in 
males in the 6 months group (88.1% versus 91.5%, P<0.05). 
The relation between sex and diameter of tuberculin 
induration showed no differences in all age groups. 
3.2. Correlation between tuberculin induration and scar 
formation
  There was a positive correlation (r=0.17, P<0.05) between 
scar formation and tuberculin induration (Figure 1). About 
90.3% of the infants with scar formation responded to 
tuberculin skin test, compared to only 33.6% of those whose 
scar formation were not visible (P<0.05). Instead, 99.3% of 
the infants with positive tuberculin skin testing exhibited 
scar formation compared to 88.0% of those who were negative 
for tuberculin reactivity (P<0.05). The infants with no scars 
more likely did not respond to tuberculin skin testing 
compared those with scars (P<0.05). The PPD negative 
subjects were more likely to develop a tiny scar or no scar 
than the subjects with a positive PPD test (P<0.05).
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Figure 1. Correlation between tuberculin induration and scar 
formation.
Correlations between BCG scar formation and tuberculin induration 
were estimated using Pearson’s correlation coefficient, due to the 
normal distribution. There was a positive correlation (r= 0.17, P<0.05) 
between scar formation and tuberculin induration according to all 
infants (n=5 629). 
Table 1
Status of scar formation and tuberculin testing in different age groups.
Age group
Number
(Male/Female)
Frequency of scar formation 
(%)
Frequency of diameter of tuberculinin induration 
(%) Diameter of tuberculinin 
induration (cm)
Invisible 曑0.2 cm >0.2 cm <0.5 cm 0.5-1.5 cm 曒1.5 cm
3 months 1 900(1 044/856) 1.7 6.5 91.8 10.1 89.2 0.7  0.776依0.32a
6 months 1 875(1 059/816) 2.2 9.4 88.4 10.4 89.2 0.4  0.777依0.30a
12 months 1 854(1 011/843) 2.0 5.4 92.6 12.0 87.8 0.2  0.751依0.32b
Total 5 629(3 114/2 515) 2.0 7.1 90.9 10.8 88.7 0.5
According to all infants (n=5 629), frequencies of scar formation and diameter of tuberculin were calculated. Diameter of tuberculin induration of 
different age groups is expressed as mean依SD and was analyzed by one-way ANOVA. Means in the last column with different superscript letters 
are significantly different (P<0.05). 
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3.3. Effect of VA combined VD on in vivo PPD response
  Background characteristics were compared between the 
two intervention groups (Table 2). Sex, mean age, and other 
background factors of the infants did not differ between the 
supplementation group and control group. After 3 months, all 
597 intervention subjects were returned to give PPD test and 
check the response. Compararison between the intervention 
groups is shown in Table 3. The rate of response to PPD was 
higher in the supplementation group than in the control 
group (P<0.05), and the prevalence ratio of PPD response 
was 1.07 (95% CI: 1.02-1.12). At 15 months of age, 97.4% 
responded to PPD in the supplementation group, compared 
to 89.7% in the control group (P<0.05), and the prevalence 
ratio of PPD response was 1.09 (95% CI: 1.01-1.17). The 
males and females in the supplementation group showed 
higher ratio of PPD response than those in the control group 
(P<0.05) respectively, and the prevalence ratios of PPD 
response for the supplementation group compared with that 
for the control group was 1.07 (95% CI: 1.01-1.13) for the 
males and 1.08 (95% CI: 1.00-1.17) for the females.
  The rate of response to PPD was not different between 
sexes within the supplementation group and control group 
respectively (Table 4). For the supplementation group, the 
mean diameter of tuberculin induration was larger in the 
females than in the males (P<0.05) before the intervention. 
However, after 3 months of intervention, the males got larger 
tuberculin induration than the females (P<0.05). For the 
control group, the mean diameter of tuberculin induration 
was larger in the females than in the males (P<0.05) 
before the intervention, while no significant difference 
was found between the males and females after 3 months. 
The interaction analysis between two groups showed no 
differences in sexes.
4. Discussion
  The BCG protective efficacy has been widely reported in 
Asia[14]. Despite continued efforts have been directed to 
improve TB control programs at the national level, China 
remains as a major region with the greatest burden of TB. As 
TB prevalence rate was high in children[15], BCG vaccination 
is still the important strategy in China before the appearance 
Table 2
Background factors of intervention groups.
Group
Sex percentage
(%)
Age percentage 
(%) Body length 
(cm)
Weight 
(kg)
Head circumference 
(cm)
BCG scar formation 
(cm)
DTIa (cm)
Male Female 3 months 6 months 12 months
VA combined 
VD group
53.7   46.3*   28.9* 33.6 37.5   68.1依7.0* 8.9依1.9*   43.9依2.8*   0.31依0.18*   0.19依0.15*
Control group 55.9 44.1 31.4 31.7 36.9 67.9依7.2 9.0依2.0 43.9依2.7 0.31依0.17 0.20依0.19
The background factors except sex and age are expressed as mean依SD. For intervention, 307 infants were enrolled in the supplementation 
group and 290 in the control group. The subjects in the VA combined VD group received vitamin A (VA) combined vitamin D (VD) drops which 
contained 1 500 IU VA  and 500 IU VD, 1 capsule/d. The background factors of the intervention groups before intervention were analyzed by 
Student's t test. The sex, mean age and other background factors of the infants did not differ between the supplementation group and control 
group (P >0.05). aDIT: Diameter of tuberculinin duration.
Table 3
Prevalence of PPD response in intervention groups after 3-month intervention (%).
Group Total
Age Sexes
6 months 9 months 15 months Male Female
VA combined VD group   96.1(307)* 95.5(89) 95.1(103)   97.4(115)*   97.6(165)*   94.4(162)*
Control group 89.7(290) 89.0(91) 90.2(92) 89.7(107) 91.4(142) 87.5(128)
Prevalence ratio (95% CI) 1.07(1.02-1.12) 1.09(1.01-1.17) 1.07(1.01-1.13) 1.08(1.00-1.17)
Chi-square test was used. * indicates significant differences at 0.05 level (vs the control group). The data following the percentages are the 
number of infants with PPD response.
Table 4
Comparison on PPD response between different sexes of intervention groups before and after intervention.
Group Sex Rate of PPD response (%)
Diameter of tuberculin induration (cm)
Before intervention After intervention
VA combined VD group Male (n=165)   97.6*   0.16依0.15*   0.73依0.21*
Female (n=142) 94.4 0.23依0.14 0.67依0.20
Control group Male (n=162)   91.4*   0.17依0.15* 0.72依0.21
Female (n=128) 87.5 0.23依0.14 0.68依0.22
* indicates significant differences at 0.05 level (vs the females in the same group). Diameter of tuberculin induration (mean依SD) was analyzed 
between the sexes by Student's t test. 
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of more efficient vaccines. In our study, we found there 
was a positive correlation between tuberculin induration 
and scar formation among infants. This finding is similar 
to a study which confirmed a highly positive correlation 
between scar formation and vaccination tuberculin 
sensitivity among preschool children[16]. The size of BCG 
scar was associated with considerable enhancement in 
sensitization to tuberculin[17,18]. Studies showed that 98% out 
of 361 Asian neonates[19] and 95% of 193 Asian vaccinees[20] 
revealed a positive post-vaccination tuberculin. Conflicting 
results from the United Kingdom showed that only 45%-
46% of vaccinated children were positive in Mantoux when 
being tested between the ages of 3 months and 2 years[21]. 
Although the tuberculin state after vaccination was not 
generally thought to influence the protection offered by BCG, 
the higher increase of TB was in the mainly unimmunized 
cohorts born in a European country after 1975, compared 
with the mainly BCG immunized cohorts born there between 
1969 and 1974[22]. It is too difficult to collect blood samples 
to evaluate immunological activity of infants in large 
population, because blood collecting is more harmful for 
infants and low income countries may not afford the cost. We 
think BCG scar and tuberculin induration are more harmless 
and visible for evaluation. According to previous study, 
our findings confirm the trends that the prevalence of PPD 
positivity was also consistently higher among individuals 
compared to those without a BCG scar. 
  In Malawian studies, boys develop scars and PPD responses 
more frequently than girls[8]. Our investigation showed 
larger scar formation in the males than in the females in the 
6 months group, higher rate of response to PPD test in the 
males than in the females in the 3 months group, but higher 
rate of response to PPD test in the females than in the males 
in the 6 months group. Totally, the rate of all infants was not 
different between sexes. The relationship between sexes and 
PPD response is not clear in our study and needs further 
investigation. 
  Studies in north and south China showed a high prevalence 
of VA and VD deficiency among children and infants[23,24]. 
The high-risk groups were young, dwelled in rural areas 
with low socioeconomic status, poorly trained doctors 
and limited medical equipment, had parents with poor 
education and did not take a regular VA and VD containing 
supplement. It is associated with high prevalence of TB 
in rural of China[25]. Epidemiological relationships and 
largely clinical observation showed a protective role of VD 
in TB[26]. A study demonstrated that a single dose of 2.5 
mg VD for adults significantly enhanced immunity against 
mycobacteria[27]. Studies from Asia suggested that it might 
be beneficial to provide VA supplementation at birth to 
decrease mortality[9,28]. A series of studies in Africa offered 
high-dose VA (200 000 IU/4 months or 50 000 IU/month) 
plus BCG vaccination and showed VA supplementation 
with BCG vaccination does not appear to interfere with the 
long-term immune response to BCG. VA supplementation 
at birth can not reduce the mortality and seems to increase 
the mortality of girls, and diphtheria-tetanus-pertussis 
vaccinations appeared to affect the rise in retinol binding 
protein concentrations negatively in girls[11,29]. In our study, 
we chose 1 500 IU VA and 500 IU VD for 3 months, lower 
than the tolerable upper intake levels (6 667 IU and 800 IU
respectively) and far more lower than the VA provided by 
studies held in Africa[11,29], so the safety can be insured. 
According to the above study, many researches depended 
on VA or VD supplementation and there are both VA and 
VD deficiency in China, so we chose VA combined VD 
supplementation in our study. In our findings, the rate 
of response to PPD was higher in the VA combined VD 
supplementation group than in the control group. It proved 
that proper dose of VA and VD supplementation may be 
beneficial to enhance BCG effects on TB prevention. Two 
trials in Guinea-Bissau showed that VA supplementation 
at birth showed no effect and estimated a negative effect 
on girls and a potentially beneficial effect on boys. There 
are indications that boys may have a more pronounced 
Th1 profile than girls since they have a stronger delayed 
hypersensitivity response[10]. For our supplementation group, 
the mean diameter of tuberculin induration was larger in the 
females than in the males before the intervention, but the 
males got larger tuberculin induration than the females after 
3 months of intervention. It indicated that the males may 
get better effects of TB protection after VA combined VD 
supplementation. 
  In conclusion, the correlation between tuberculin 
induration and scar formation indicated the BCG scar 
formation may be an useful tool to evaluate the effect of TB 
prevention. VA combined VD supplementation could raise 
the rate of PPD positive response and may be beneficial for 
countries with high prevalence of TB and related VA and 
VD deficiency. Further study should continue to confirm the 
effect of VA combined VD in TB prevention by follow-up, 
longitudinal investigation. 
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